SARS-CoV-2 vaccines
Control of the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will require one or more vaccines. Currently, numerous SARS-CoV-2 vaccines are in either pre-clinical or clinical development. Twenty are in fase III development. In this review we summarise available safety and efficacy data of two RNA based vaccines, two non-replication competent vector-based vaccine, one inactivated whole-virus vaccine, and one subunit. All being either approved or nearing approval.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:183 |
|---|---|
| Enthalten in: |
Ugeskrift for laeger - 183(2021), 10 vom: 08. März |
| Sprache: |
Dänisch |
|---|
| Beteiligte Personen: |
Benfield, Thomas Lars [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.03.2021 Date Revised 25.03.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM322906385 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322906385 | ||
| 003 | DE-627 | ||
| 005 | 20231225183031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||dan c | ||
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322906385 | ||
| 035 | |a (NLM)33734065 | ||
| 035 | |a (PII)V01210052 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dan | ||
| 100 | 1 | |a Benfield, Thomas Lars |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 vaccines |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2021 | ||
| 500 | |a Date Revised 25.03.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Control of the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will require one or more vaccines. Currently, numerous SARS-CoV-2 vaccines are in either pre-clinical or clinical development. Twenty are in fase III development. In this review we summarise available safety and efficacy data of two RNA based vaccines, two non-replication competent vector-based vaccine, one inactivated whole-virus vaccine, and one subunit. All being either approved or nearing approval | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Helweg-Larsen, Jannik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ugeskrift for laeger |d 1945 |g 183(2021), 10 vom: 08. März |w (DE-627)NLM000011185 |x 1603-6824 |7 nnns |
| 773 | 1 | 8 | |g volume:183 |g year:2021 |g number:10 |g day:08 |g month:03 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 183 |j 2021 |e 10 |b 08 |c 03 | ||